GHRS

GH ResearchC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

Current thesis

The constructive view is that GH001 now has peer-reviewed Phase 2b data, the FDA hold has been lifted, and cash was reported at $280.7 million at year-end 2025, giving GHRS a funded shot at moving into a global pivotal program if FDA alignment is achieved [#PR-2026-01-05] [#PR-2026-03-05] [#PR-2026-03-25].

Posture

Mixed

Lead driver

Momentum

What changed

Momentum remains the lead driver in the composite, 7D delta +7.9.

What can break

FDA hold removal helps, but successful FDA alignment on the planned global Phase 3 design is still an unresolved execution gate.

Momentum

Value

Sentiment

Setup hits (3d)

0 · Net Neutral

AI TargetsBase $24.00 · Bull $36.00 · Bear $11.00

Data freshness

Prices

As of 2026-07-18

Fundamentals

As of 2026-07-17 • Vendor: Data Vendor v1

Scores

As of 2026-07-18 • Model: HYBRID_IC_RP

AI Memo

As of 2026-04-28 • Model: RankAlpha Sentiment Codex

Investment thesis

As of 2026-07-18

Supporting evidence

What

Grade C · Mixed

Confidence Medium · Net Neutral

Target $38.56

Why

Momentum92 · Δ7d +7.9

Value41 · Δ7d -0.1

Sentiment27 · Δ7d -9.1

So what

Balanced signals (Net Neutral). Wait for confirmation before sizing up.

Lead driver: Momentum · See technicals

Momentum

26% active weight

Current posture

7d trendSoftening

Δ7d

+7.9

Δ21d

+6.3

Value

39% active weight

Current posture

7d trendFlat

Δ7d

-0.1

Δ21d

0.0

Sentiment

34% active weight

Current posture

7d trendSoftening

Δ7d

-9.1

Δ21d

-3.0

Why this grade

Composite grade C. Momentum 92.5 / Value 41.1 / Sentiment 26.9

Fundamentals (TTM)

As of 2026-07-17

Market Cap

$1.97B

Beta

0.98

Shares Out

68.56M

P/E (TTM) · Derived

-36.3

P/S (TTM)

P/FCF (TTM) · Derived

-37.73

Rev YoY

EPS YoY

+64.1%

Gross Margin

Op Margin

Net Debt

-$280.2M

Current Ratio

23.04

As of 2026-07-18 • Updated nightlySource: Internal modelMethodology